Pivotal role of mouse mast cell protease 4 in the conversion and pressor properties of big-endothelin-1

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 1, 2013, Pages 31-37

  Houde, Martin ^a   Jamain, Marc David ^a   Labonté, Julie ^a   Desbiens, Louisane ^a   Pejler, Gunnar ^b   Gurish, Michael ^c   Takai, Shinji ^d   D'Orléans Juste, Pedro ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^c HARVARD UNIVERSITY   (United States)

^d OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMASE INHIBITOR; ENDOTHELIN 1; MAST CELL PROTEASE 4; PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; TISSUE DISTRIBUTION; UPREGULATION;

ANIMALS; AORTA; CARBOXYPEPTIDASES A; DRUG RESISTANCE; ENDOTHELIN-1; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART VENTRICLES; HEMODYNAMICS; ISOENZYMES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN SPECIFICITY; PEPTIDE FRAGMENTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SULFONAMIDES; THIOPHENES; THIORPHAN;

EID: 84879306713     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.202275     Document Type: Article

References (49)

1. Andersson MK, Karlson U, and Hellman L (2008) The extended cleavage specificity of the rodent beta-chymases rMCP-1 and mMCP-4 reveal major functional similarities to the human mast cell chymase. Mol Immunol 45:766-775.
2. Arai H, Hori S, Aramori I., Ohkubo H, and Nakanishi S (1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348:730-732.
3. Baraniuk JN, Ohkubo K, Kwon O.J., Mak J., Ali M, Davies R, Twort C., Kaliner M, Letarte M, and Barnes PJ (1995) Localization of neutral endopeptidase (NEP) mRNA in human bronchi. Eur Respir J 8:1458-1464.
4. Butz GM and Davisson RL (2001) Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol Genomics 5:89-97.
5. Carlson SH and Wyss JM (2000) Long-term telemetric recording of arterial pressure and heart rate in mice fed basal and high NaCl diets. Hypertension 35:E1-E5.
6. Caughey GH (2007) Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 217:141-154.
7. D'Orléans-Juste P, Houde M, Rae GA, Bkaily G, Carrier E, and Simard E (2008) Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies. Vascul Pharmacol 49:51-62.
8. D'Orléans-Juste P, Plante M, Honoré JC, Carrier E, and Labonté J (2003) Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol 81:503-510.
9. Davenport AP and Maguire JJ (2006) Endothelin. Handb Exp Pharmacol 176: 295-329.
10. Denault JB, Claing A, D'Orléans-Juste P, Sawamura T, Kido T, Masaki T, and Leduc R (1995) Processing of proendothelin-1 by human furin convertase. FEBS Lett 362: 276-280.
11. Ergul A, Portik-Dobos V, Giulumian A.D., Molero MM, and Fuchs LC (2003) Stress upregulates arterial matrix metalloproteinase expression and activity via endo-thelin A receptor activation. Am J Physiol Heart Circ Physiol 285:H2225-H2232.
12. Fecteau M-H, Honoré J-C, Plante M, Labonté J, Rae GA, and D'Orléans-Juste P (2005) Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. Hypertension 46:87-92.
13. Fernandez-Patron C., Radomski MW, and Davidge ST (1999) Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85:906-911.
14. Fleming I (2006) Signaling by the angiotensin-converting enzyme. Circ Res 98:887-896.
15. Groschwitz KR, Ahrens R, Osterfeld H., Gurish MF, Han X, Abrink M, Finkelman F.D., Pejler G., and Hogan SP (2009) Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4- dependent mechanism. Proc Natl Acad Sci USA 106:22381-22386.
16. Hanson GC, Andersson KE, Gyllstedt E, Högestätt ED, and Lindberg BF (1997) Hydrolysis of big endothelin-1 by a serine protease in the membrane fraction of human lung. Regul Pept 68:63-69.
17. Hayasaki-Kajiwara Y., Naya N, Shimamura T., Iwasaki T, and Nakajima M (1999) Endothelin generating pathway through endothelin1-31 in human cultured bronchial smooth muscle cells. Br J Pharmacol 127:1415-1421.
18. Inoue N, Muramatsu M, Jin D., Takai S, Hayashi T, Katayama H., Kitaura Y, Tamai H, and Miyazaki M (2009) Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis 204:359-364.
19. Jin D, Takai S, Yamada M., Sakaguchi M, Kamoshita K, Ishida K., Sukenaga Y, and Miyazaki M (2003) Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res 60:413-420.
20. Kaartinen M, Penttilä A, and Kovanen PT (1994) Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 90:1669-1678.
21. Koide Y, Tatsui A, Hasegawa T., Murakami A, Satoh S, Yamada H., Kazayama S, and Takahashi A (2003) Identification of a stable chymase inhibitor using a phar-macophore-Based database search. Bioorg Med Chem Lett 13:25-29.
22. Leask A (2010) Potential therapeutic targets for cardiac fibrosis: TGFbeta, angio-tensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106:1675-1680.
23. Mangiapane ML, Rauch AL, MacAndrew J.T., Ellery SS, Hoover KW, Knight DR, Johnson H.A., Magee WP, Cushing DJ, and Buchholz RA (1994) Vasoconstrictor action of angiotensin I-convertase and the synthetic substrate (Pro11, D-Ala12)-angiotensin I. Hypertension 23:857-860.
24. Mawatari K, Kakui S, Harada N., Ohnishi T, Niwa Y, Okada K., Takahashi A, Izumi K, and Nakaya Y (2004) Endothelin-1(1-31) levels are increased in atherosclerotic lesions of the thoracic aorta of hypercholesterolemic hamsters. Atherosclerosis 175: 203-212.
25. McMahon EG, Palomo MA, Moore W.M., McDonald JF, and Stern MK (1991) Phos-phoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci USA 88:703-707.
26. Milnor WR (1989) Hemodynamics, Williams & Wilkins, Baltimore, MD.
27. Montanari A, Biggi A, Carra N., Ziliotti M, Fasoli E, Musiari L., Perinotto P, and Novarini A (2003) Endothelin-A receptors mediate renal hemodynamic effects of exogenous Angiotensin II in humans. Hypertension 42:825-830.
28. Nakano A, Kishi F, Minami K., Wakabayashi H, Nakaya Y, and Kido H (1997) Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 159: 1987-1992.
29. Palaniyandi SS, Nagai Y, Watanabe K., Ma M, Veeraveedu PT, Prakash P, Kamal F.A., Abe Y., Yamaguchi K, and Tachikawa H, et al (2007) Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. Exp Biol Med (Maywood) 232:1213-1221.
30. Paul M, Poyan Mehr A, and Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86:747-803.
31. Pejler G, Rönnberg E, Waern I., and Wernersson S (2010) Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 115:4981-4990.
32. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
33. Rouet-Benzineb P., Gontero B, Dreyfus P., and Lafuma C (2000) Angiotensin II induces nuclear factor-kappa B activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol 32:1767-1778.
34. Sakurai T, Yanagisawa M, Takuwa Y., Miyazaki H, Kimura S, Goto K., and Masaki T (1990) Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348:732-735.
35. Simard E, Jin D, Takai S., Miyazaki M, Brochu I, and D'Orléans- Juste P (2009) Chymase-dependent conversion of Big endothelin-1 in the mouse in vivo. J Pharmacol Exp Ther 328:540-548.
36. Sun J, Zhang J, Lindholt J.S., Sukhova GK, Liu J, He A, Abrink M., Pejler G, Stevens RL, and Thompson RW, et al (2009) Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 120:973-982.
37. Takai S, Jin D, and Miyazaki M (2010) Chymase as an important target for preventing complications of metabolic syndrome. Curr Med Chem 17:3223-3229.
38. Takai S, Jin D, and Miyazaki M (2011) Targets of chymase inhibitors. Expert Opin Ther Targets 15:519-527.
39. Takai S, Jin D, Sakaguchi M., Katayama S, Muramatsu M, Sakaguchi M., Matsumura E, Kim S, and Miyazaki M (2003) A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl) -4-oxo-azetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 305:17-23.
40. Tchougounova E, Pejler G, and Abrink M (2003) The chymase, mouse mast cell protease 4, constitutes the major chymotrypsin-like activity in peritoneum and ear tissue. A role for mouse mast cell protease 4 in thrombin regulation and fibronectin turnover. J Exp Med 198:423-431.
41. Thorin E and Clozel M (2010) The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol 60:1-26.
42. Tsunemi K, Takai S, Nishimoto M., Jin D, Sakaguchi M, Muramatsu M., Yuda A, Sasaki S, and Miyazaki M (2004) A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[3, 4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl]acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther 309:879-883.
43. Urata H, Boehm KD, Philip A, Kinoshita A., Gabrovsek J, Bumpus FM, and Husain A (1993) Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 91:1269-1281.
44. Urata H, Kinoshita A, Misono K.S., Bumpus FM, and Husain A (1990) Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265:22348-22357.
45. Walsh SK, Kane KA, and Wainwright CL (2009) Mast cell degranulation - a mechanism for the anti-arrhythmic effect of endothelin-1? Br J Pharmacol 157:716-723.
46. Wypij DM, Nichols JS, Novak P.J., Stacy DL, Berman J, and Wiseman JS (1992) Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem Pharmacol 43:845-853.
47. Yanagisawa H, Hammer RE, Richardson J.A., Emoto N., Williams SC, Takeda Si, Clouthier DE, and Yanagisawa M (2000) Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 105:1373-1382.
48. Yanagisawa M, Kurihara H, Kimura S., Tomobe Y, Kobayashi M, Mitsui Y., Yazaki Y, Goto K, and Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415.
49. Yoshizumi M, Kim S, Kagami S., Hamaguchi A, Tsuchiya K, Houchi H., Iwao H, Kido H, and Tamaki T (1998) Effect of endothelin-1 (1-31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Br J Pharmacol 125:1019-1027.